NCT00451412

A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients

A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 3,254 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to provide efficacy and safety data for certoparin in the prophylaxis of venous thromboembolism in immobilized, acutely ill medical patients.

Conditions

• Thromboembolism

Interventions

Type	Name	Description
DRUG	Certoparin	3000 U anti XA of certoparin in 0.3 ml solution, once daily
DRUG	Unfractionated Heparin	solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily

Timeline

• Start date: 2007-01-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2007-03-23
• Last updated: 2012-07-25

Locations

1 site across 1 country: Germany